Detalhe da pesquisa
1.
Increased Population Risk of AIP-Related Acromegaly and Gigantism in Ireland.
Hum Mutat
; 38(1): 78-85, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27650164
2.
Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology.
Echo Res Pract
; 6(1): G1-G8, 2019 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30825409
3.
Circulating aryl hydrocarbon receptor-interacting protein (AIP) is independent of GH secretion.
Endocr Connect
; 8(4): 326-337, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30830858
4.
Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors.
Oncogene
; 38(27): 5381-5395, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30867568
5.
Somatic GPR101 Duplication Causing X-Linked Acrogigantism (XLAG)-Diagnosis and Management.
J Clin Endocrinol Metab
; 101(5): 1927-30, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26982009
6.
A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.
J Clin Endocrinol Metab
; 101(11): 4189-4194, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27571182
7.
Regulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas.
PLoS One
; 10(2): e0117107, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25658813